- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03783585
Feasibility of Web-based CBT-I Intervention in Individuals With Multiple Sclerosis
26. august 2019 opdateret af: Catherine Siengsukon, PT, PhD, University of Kansas Medical Center
Assessment of the Feasibility of a Web-based CBT-I Intervention to Improve Sleep Quality and Fatigue in Individuals With Multiple Sclerosis
Forty individuals with multiple sclerosis (MS) will be randomly assigned to a 6-week web-based cognitive behavior therapy for insomnia intervention (wCBT-I) or to wCBT-I plus biweekly support meetings with research personnel via phone or video.
Questionnaires will be used to assess sleep quality, fatigue, and satisfaction.
Recruitment, retention, attrition, adherence, and safety information will also be collected.
This study is significant because addressing insomnia symptoms through CBT-I could be a low-cost, low-risk, non-pharmacological options for improving sleep quality and MS symptoms in individuals with MS.
This study is innovative because CBT-I has never been delivered via a web-based application to individuals with MS which may increase access to services.
Studieoversigt
Status
Afsluttet
Betingelser
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
44
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- Catherine Siengsukon
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 80 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- 18-80 years old
- diagnosis of MS by physician
- report of difficulty falling asleep, maintaining sleep, or waking up too early at least 3 nights/week for the past 6 months
- ≥10 on Insomnia Severity Index (ISI)
- English speaking
- reports access to internet service and phone
- has a high school diploma to serve as a proxy measurement of reading ability to ensure adequate reading ability to participate in the study.
Exclusion Criteria:
- known untreated sleep disorder (such as sleep apnea or restless leg syndrome)
- >3 on STOP BANG indicating risk of sleep apnea
- increased risk of restless leg syndrome
- nervous system disorder other than MS
- relapse and/or corticosteroid use in past 8 weeks
- score of ≥15 on the Patient Health Questionnaire (PHQ-9) indicating severe depression or endorse any suicidal ideation (answer 1, 2 or 3 on #9 of the PHQ-9)
- performs shift-work.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: cognitive behavioral therapy for insomnia (CBT-I)
Participants randomized to this arm will participate in a 6-week web-based cognitive behavioral therapy for insomnia (CBT-I) program.
|
The web-based CBT-I program is a 6-week interactive, online program that delivers typical CBT-I treatment techniques of stimulus control, sleep restriction, behavioral modifications, and cognitive restructuring.
|
Eksperimentel: CBT-I + biweekly support
Participants randomized to this arm will participate in a 6-week web-based CBT-I program.
In addition, biweekly support consisting of one-on-one, semi-structured, online video-chat sessions (via HIPAA-compliant Zoom) or phone calls will be conducted every other week.
|
The web-based CBT-I program is a 6-week interactive, online program that delivers typical CBT-I treatment techniques of stimulus control, sleep restriction, behavioral modifications, and cognitive restructuring.
Individuals randomized into the CBT-I + biweekly support will participate in CBT-I as described as well as a biweekly phone call or video call with research personnel for motivational interviewing.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
change in Insomnia Severity Index (ISI)
Tidsramme: baseline and week 8
|
The ISI is a valid and reliable measure of sleep difficulties and consists of 7 questions each rated on a 0-4 scale.
The range of scores on the ISI is 0-28, with ≥10 suggesting clinical insomnia
|
baseline and week 8
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
change in Pittsburgh Sleep Quality Index (PSQI)
Tidsramme: baseline and week 8
|
The PSQI is a well-validated and reliable measure of sleep quality and consists of 9 items within 7 sleep categories.
The 7 sleep category scores are summed to form a single global score ranging from 0-21.
A global score of >5 reflects poor sleep quality
|
baseline and week 8
|
change in Modified Fatigue Impact Scale (MFIS)
Tidsramme: baseline and week 8
|
The MFIS consists of 21 items with 3 subscales: physical, cognitive, and psychosocial.
The score on the 21 items are scored with a range of 0-84 with a higher score indicating a greater impact of fatigue.
|
baseline and week 8
|
change in Fatigue Severity Scale (FSS)
Tidsramme: baseline and week 8
|
Fatigue Severity Scale (FSS) assesses the impact of fatigue on activities for the week prior and consists of 9 questions.
The mean of the 9 scores is calculated with a range of 0-7.
|
baseline and week 8
|
change in Multiple Sclerosis Impact Scale (MSIS)
Tidsramme: baseline and week 8
|
MSIS-29 is total of 29 items scale, with subscales of physical (20 items) and psychological (9 items).
Responses computed in a range from 0-100, and higher scores indicating a worse quality of life due to physical and physiological impacts of MS.
|
baseline and week 8
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. oktober 2018
Primær færdiggørelse (Faktiske)
20. august 2019
Studieafslutning (Faktiske)
20. august 2019
Datoer for studieregistrering
Først indsendt
1. oktober 2018
Først indsendt, der opfyldte QC-kriterier
18. december 2018
Først opslået (Faktiske)
21. december 2018
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
28. august 2019
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
26. august 2019
Sidst verificeret
1. januar 2019
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- STUDY00142464
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Multipel sclerose
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeKlassisk Hodgkin lymfom | Lymfocytrigt klassisk Hodgkin-lymfom | Ann Arbor Stage IB Hodgkin lymfom | Ann Arbor Stage II Hodgkin lymfom | Ann Arbor Stage IIA Hodgkin lymfom | Ann Arbor Stage IIB Hodgkin lymfom | Ann Arbor Stage I Hodgkin lymfom | Ann Arbor Stage I Mixed Cellularity Klassisk Hodgkin-lymfom og andre forholdForenede Stater
Kliniske forsøg med Cognitive behavioral therapy for insomnia
-
Medical University of South CarolinaDrug Abuse Research Training ProgramAfsluttet
-
University Hospital, Clermont-FerrandNational Cancer Institute, FranceRekrutteringOphør med tobaksbrugFrankrig
-
University Hospital, Clermont-FerrandFondation de l'Avenir, FranceUkendtAfhængighed | Kokain-relaterede lidelserFrankrig
-
Universidad Nacional Autonoma de MexicoIstituto Auxologico Italiano; Medica Sur Clinic & FoundationUkendt
-
Jack Edinger, PhDNational Institute of Mental Health (NIMH); National Institutes of Health...AfsluttetPrimær søvnløshed | Insomnia Comorbid til psykiatrisk lidelseForenede Stater, Canada
-
M.D. Anderson Cancer CenterRekrutteringDepression | Kræft | Træthed | Søvn | AngstForenede Stater